Active Supportive Care and Symptom Management Grants

PI Name Organization - Company Title FOAsort ascending
Levine, Jon David University Of California, San Francisco Chronic Chemotherapy Peripheral Neuropathy: Role of Neuroplasticity and Stress
Im, Eun-Ok Emory University Cancer Pain Management: A Technology-Based Intervention for Asian American Breast Cancer Survivors RFA-NS-22-037: HEAL Initiative: Advancing Health Equity in Pain and Comorbidities
Brinkman, Tara M St. Jude Children'S Research Hospital Culturally adapted mobile treatment of chronic pain in adolescent survivors of pediatric bone sarcoma RFA-NS-22-037: HEAL Initiative: Advancing Health Equity in Pain and Comorbidities
Cheville, Andrea Lynne Mayo Clinic Rochester Achieving Equity through SocioCulturally-informed, Digitally-Enabled Cancer Pain managemeNT” (ASCENT) Clinical Trial RFA-NS-22-002: HEAL Initiative: Advancing Health Equity in Pain Management
Wang, Jing New York University School Of Medicine Optimizing the use of ketamine to reduce chronic postsurgical pain RFA-NS-20-028: HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Melemedjian, Ohannes Kevork University Of Maryland Baltimore Identification of novel targets for the treatment of chemotherapy-induced painful peripheral neuropathy RFA-NS-18-043: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment
Shen, Chan Pennsylvania State Univ Hershey Med Ctr The effects of hydrocodone rescheduling on pain management of older lung cancer patients RFA-DE-22-011: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans
Laack, Nadia N Mayo Clinic Rochester Utility of memantine in preventing cognitive dysfunction in children receiving cranial radiotherapy RFA-CA-19-033: Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors
Hu, Shuiying Ohio State University Prevention of paclitaxel-induced peripheral neuropathy with nilotinib RFA-CA-18-019: Research Answers to National Cancer Institute's (NCI) Provocative Questions
Tighiouart, Mourad Cedars-Sinai Medical Center Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical Trials RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability
Basch, Ethan M. Univ Of North Carolina Chapel Hill Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug Tolerability RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability
Gray, Robert J Dana-Farber Cancer Inst Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV) RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability
Mohile, Supriya G University Of Rochester Understanding Treatment Tolerability in Older Patients with Cancer RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability
Grace, Peter University Of Tx Md Anderson Can Ctr PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain RFA-CA-17-017: Research Answers to NCI's Provocative Questions
Prigerson, Holly Gwen Weill Medical Coll Of Cornell Univ Behavioral and Psychosocial Effects on Study Outcomes in End-Stage Cancer Treatment (BEST End-Stage Cancer Study) PAR-21-333: NCI Outstanding Investigator Award

Pages